These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 16332722)

  • 1. Signalling cell cycle arrest and cell death through the MMR System.
    O'Brien V; Brown R
    Carcinogenesis; 2006 Apr; 27(4):682-92. PubMed ID: 16332722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA mismatch repair (MMR) mediates 6-thioguanine genotoxicity by introducing single-strand breaks to signal a G2-M arrest in MMR-proficient RKO cells.
    Yan T; Berry SE; Desai AB; Kinsella TJ
    Clin Cancer Res; 2003 Jun; 9(6):2327-34. PubMed ID: 12796402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses.
    Meyers M; Wagner MW; Hwang HS; Kinsella TJ; Boothman DA
    Cancer Res; 2001 Jul; 61(13):5193-201. PubMed ID: 11431359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defective expression of the DNA mismatch repair protein, MLH1, alters G2-M cell cycle checkpoint arrest following ionizing radiation.
    Davis TW; Wilson-Van Patten C; Meyers M; Kunugi KA; Cuthill S; Reznikoff C; Garces C; Boland CR; Kinsella TJ; Fishel R; Boothman DA
    Cancer Res; 1998 Feb; 58(4):767-78. PubMed ID: 9485033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of drug resistance mediated by loss of mismatch repair by the DNA polymerase inhibitor aphidicolin.
    Moreland NJ; Illand M; Kim YT; Paul J; Brown R
    Cancer Res; 1999 May; 59(9):2102-6. PubMed ID: 10232595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of DNA mismatch repair imparts defective cdc2 signaling and G(2) arrest responses without altering survival after ionizing radiation.
    Yan T; Schupp JE; Hwang HS; Wagner MW; Berry SE; Strickfaden S; Veigl ML; Sedwick WD; Boothman DA; Kinsella TJ
    Cancer Res; 2001 Nov; 61(22):8290-7. PubMed ID: 11719462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of H(2)O(2) on cell cycle and survival in DNA mismatch repair-deficient and -proficient cell lines.
    Chang DK; Goel A; Ricciardiello L; Lee DH; Chang CL; Carethers JM; Boland CR
    Cancer Lett; 2003 Jun; 195(2):243-51. PubMed ID: 12767533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins.
    Sergent C; Franco N; Chapusot C; Lizard-Nacol S; Isambert N; Correia M; Chauffert B
    Cancer Chemother Pharmacol; 2002 Jun; 49(6):445-52. PubMed ID: 12107548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antisense inhibition of hMLH1 is not sufficient for loss of DNA mismatch repair function in the HCT116+chromosome 3 cell line.
    Chauhan DP; Yang Q; Carethers JM; Marra G; Chang CL; Chamberlain SM; Boland CR
    Clin Cancer Res; 2000 Oct; 6(10):3827-31. PubMed ID: 11051225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mismatch repair-dependent transcriptome changes in human cells treated with the methylating agent N-methyl-n'-nitro-N-nitrosoguanidine.
    di Pietro M; Marra G; Cejka P; Stojic L; Menigatti M; Cattaruzza MS; Jiricny J
    Cancer Res; 2003 Dec; 63(23):8158-66. PubMed ID: 14678970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defects of DNA mismatch repair in human prostate cancer.
    Chen Y; Wang J; Fraig MM; Metcalf J; Turner WR; Bissada NK; Watson DK; Schweinfest CW
    Cancer Res; 2001 May; 61(10):4112-21. PubMed ID: 11358834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mismatch repair proteins are activators of toxic responses to chromium-DNA damage.
    Peterson-Roth E; Reynolds M; Quievryn G; Zhitkovich A
    Mol Cell Biol; 2005 May; 25(9):3596-607. PubMed ID: 15831465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mismatch repair, G(2)/M cell cycle arrest and lethality after DNA damage.
    Aquilina G; Crescenzi M; Bignami M
    Carcinogenesis; 1999 Dec; 20(12):2317-26. PubMed ID: 10590226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Truncation of the C-terminus of human MLH1 blocks intracellular stabilization of PMS2 and disrupts DNA mismatch repair.
    Mohd AB; Palama B; Nelson SE; Tomer G; Nguyen M; Huo X; Buermeyer AB
    DNA Repair (Amst); 2006 Mar; 5(3):347-61. PubMed ID: 16338176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRCA1 activates a G2-M cell cycle checkpoint following 6-thioguanine-induced DNA mismatch damage.
    Yamane K; Schupp JE; Kinsella TJ
    Cancer Res; 2007 Jul; 67(13):6286-92. PubMed ID: 17616687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen.
    Taverna P; Liu L; Hanson AJ; Monks A; Gerson SL
    Cancer Chemother Pharmacol; 2000; 46(6):507-16. PubMed ID: 11138465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interactions of the DNA mismatch repair proteins MLH1 and MSH2 with c-MYC and MAX.
    Mac Partlin M; Homer E; Robinson H; McCormick CJ; Crouch DH; Durant ST; Matheson EC; Hall AG; Gillespie DA; Brown R
    Oncogene; 2003 Feb; 22(6):819-25. PubMed ID: 12584560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The base excision repair enzyme MED1 mediates DNA damage response to antitumor drugs and is associated with mismatch repair system integrity.
    Cortellino S; Turner D; Masciullo V; Schepis F; Albino D; Daniel R; Skalka AM; Meropol NJ; Alberti C; Larue L; Bellacosa A
    Proc Natl Acad Sci U S A; 2003 Dec; 100(25):15071-6. PubMed ID: 14614141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The mismatch repair system is required for S-phase checkpoint activation.
    Brown KD; Rathi A; Kamath R; Beardsley DI; Zhan Q; Mannino JL; Baskaran R
    Nat Genet; 2003 Jan; 33(1):80-4. PubMed ID: 12447371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents.
    Brown R; Hirst GL; Gallagher WM; McIlwrath AJ; Margison GP; van der Zee AG; Anthoney DA
    Oncogene; 1997 Jul; 15(1):45-52. PubMed ID: 9233776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.